Clinilabs invites you to their event
Hosted by
Todd has approximately 15 years of experience in the CRO industry working for both midsize and large organizations. His experience has included serving in business development, account development, inside sales, and proposal development job capacities.
Laura has been working in pharmaceutical and CRO business development for more than 20 years. Business development affords her the opportunity to establish and build client relationships and to work with Clinilabs' team to provide solutions for client challenges in drug development.
Patrick has working with Clinilabs for over 7 years. His role is to identify strategic opportunities that leverage the full experience and expertise of the Clinilabs’ team and to help foster ongoing relationships that mutually embody the Clinilabs core values.
Ms. Allison House-Gecewicz brings over 20 years of experience in clinical trials project management as well as 5 years of experience in clinical monitoring and trial coordination.
Ms. Jeanine Falinski, VP of Strategy and Corporate Development, has more than 20 years of experience in the pharmaceutical industry. Jeanine graduated from Emerson College with a degree in New Media and Marketing, later on receiving her MBA in Pharmaceutical Management from Drexel University.
Susan has over 20 years of experience in the pharmaceutical industry developing strategic business development relationships. Currently, her focus is dedicated to identifying, building, and managing these relationships to provide Clinilabs with a healthy pipeline of full-service CRO opportunities.
Gary Zammit is a neuroscientist and sleep specialist who founded Clinilabs Drug Development Corporation in 2001. He is widely recognized as a key opinion leader in the field of sleep medicine, and has been involved in the development of new drugs to treat sleep disorders such as narcolepsy, insomnia, excessive sleepiness, and circadian rhythm disorders.
We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development. We are dedicated to bringing new therapies to patients living with mental health, neurological and substance abuse disorders.
